Metformin HMG-CoA Dual-Release Tablet Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current combination formulations of metformin and HMG-CoA reductase inhibitors face challenges in achieving stable and controlled release rates, with metformin's high water solubility leading to rapid release and gastrointestinal issues, and HMG-CoA reductase inhibitors being prone to decomposition and oxidation, complicating the development of a stable and effective dual-release formulation.
Innovation Solution
A two-phase system comprising granules of metformin coated with a swellable polymer and a water-insoluble polymer film, combined with an immediate-release composition of HMG-CoA reductase inhibitor, to control the release rates and prevent physical and chemical reactions, ensuring stable and effective delivery of both drugs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If metformin is formulated as a conventional fast-release tablet, then it can be easily manufactured and administered, but it causes rapid release leading to excessive drop in blood glucose levels and gastrointestinal disorders
Solution Approach 1:
The metformin tablet is divided into two distinct layers: a fast-release layer containing immediate-release metformin for rapid absorption, and a sustained-release layer containing sustained-release metformin for prolonged release. This segmentation allows each layer to perform its specific function independently, achieving both rapid onset and sustained effect without the adverse effects of complete fast-release formulation.
Solution Approach 2:
Different regions of the tablet are given different release properties: the fast-release layer provides immediate drug release for quick blood glucose control, while the sustained-release layer provides controlled, prolonged release for maintaining stable blood glucose levels. This local differentiation of release characteristics resolves the contradiction between rapid action and stable control.
2Reliability
If metformin is formulated as a sustained-release tablet using water-insoluble carriers or polymer membranes, then rapid release is prevented, but the hydration rate of the polymer is slow causing initial burst release and requiring very large amounts of polymer
Solution Approach 1:
The sustained-release layer uses a composite formulation combining hydrophilic polymers with specific viscosity ranges (100-10,000 cP) and controlled pore-forming agents. This composite approach creates a matrix that provides sustained release without requiring excessive polymer quantities, as the pore-forming agents create channels that facilitate drug release while the hydrophilic polymer provides the sustained-release mechanism.
3Ease of operation
If HMG-CoA reductase inhibitor is combined with metformin in a single formulation, then drug compliance is improved, but the HMG-CoA reductase inhibitor is prone to decomposition and oxidation
Solution Approach 1:
The combination tablet is segmented into distinct layers: the metformin layers (fast-release and sustained-release) are separated from the HMG-CoA reductase inhibitor layer. This physical segmentation prevents direct interaction between metformin and the HMG-CoA reductase inhibitor, reducing the risk of decomposition and oxidation of the latter while maintaining improved drug compliance through single-tablet administration.
Solution Approach 2:
Inert materials such as starch, cellulose, or gelatin are used as intermediate layers or coating materials between metformin and HMG-CoA reductase inhibitor. These intermediary substances act as barriers that prevent direct contact and potential adverse reactions between the two drugs, thereby maintaining the stability of the HMG-CoA reductase inhibitor while enabling combination therapy.
4Reliability
If swellable polymer with high viscosity is used for sustained-release metformin, then release control is achieved, but it delays the release of HMG-CoA reductase inhibitor requiring large amounts of polymer
Solution Approach 1:
The formulation uses localized viscosity control where the sustained-release layer employs swellable polymer with controlled viscosity (100-10,000 cP) to achieve metformin sustained-release, while the fast-release layer uses low-viscosity materials and pore-forming agents to ensure rapid HMG-CoA reductase inhibitor release. This local differentiation of viscosity properties allows both release profiles to coexist in the same tablet without mutual interference.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach inhibits initial burst release, improves drug compliance, and maintains stability and release rates, providing a balanced two-phase system for sustained and immediate release, enhancing administration convenience and reducing adverse reactions.
Implementation Method 1
granules of metformin coated with a swellable polymer
Implementation Method 2
coated with a water-insoluble polymer film
Data Source
Figure 1~2
Figure 3
AI summary
The present invention relates to a combination formulation containing metformin for treating non-insulin-dependent diabetes and an HMG-CoA reductase inhibitor for treating dyslipidemia. The present invention provides a combination formulation and a method for preparing the combination formulation, wherein the combination formulation contains metformin and an HMG-CoA reductase inhibitor, and has effectively improved stability by blocking physical and chemical reactions between the active ingredients while securing the stable release of respective active ingredients.